

**REMARKS**

Claims 1-21, 22-24 and 27-30 are currently pending. Claims 25-26 are cancelled and claims 1-22 and 24 are withdrawn. Claim 22 is amended to independent form and to conform to US practice. Claims 27-30 are supported throughout the specification and specifically in original claims 18-21. No new matter is introduced.

The Examiner has required restriction of the claims into Group I, namely claims 1-21 and 24 or Group II, namely claims 22-23. Applicants hereby elect the Examiner's designated Group II, claims 22-23 and newly added claims 27-30 directed to ectoparasitocidal compositions. The elected species is pyrimidines of formula I as indicated by the Examiner on page 3 of the current Office Action.

Applicants offer that it would not be unduly burdensome on the part of the Examiner to examine all species. However, for the sake of progressing prosecution on this case, Applicants elect the species designated herein. Each of the claims, 22-23 and 27-30 are directed to the elected species. Upon allowance of a generic claim, Applicants respectfully request consideration of additional species.


Applicant authorizes the Commissioner to charge all fees due to Deposit Account 50-4389. Applicant also requests that all correspondence be directed to the address associated with Customer Number 74479 which is currently as follows:

Novartis Animal Health US, Inc.  
3200 Northline Avenue, Suite 300  
Greensboro, NC 27408

Applicants believe this case is now in condition for review and Allowance. The Examiner is requested to contact the below signed attorney should any questions arise.

Respectfully submitted,


Date: July 14, 2008

By:   
Kimberly H. Parker  
Attorney for Applicants  
Reg. No. 47,843

Novartis Animal Health US, Inc.  
3600 Northline Avenue, Suite 300  
Greensboro, NC 27408  
(336) 387-1443

Certificate of Transmission

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent & Trademark Office at (571) 273-8300 on July 14, 2008.

 Kimberly H. Parker July 14, 2008